In 2017, major advances in the treatment of non-small-cell lung cancer (NSCLC) continued to emanate from the fields of molecularly targeted therapy and immunotherapy. In the former, new drugs with improved efficacy and reduced toxicity entered the clinic; in the latter, immune-checkpoint inhibition proved efficacious after chemoradiotherapy for stage III disease, but had disparate results in the frontline treatment of stage IV disease.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Thomas, A., Liu, S. V., Subramaniam, D. S. & Giaccone, G. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat. Rev. Clin. Oncol. 12, 511–526 (2015).
Mok, T. S. et al. Osimertinib or platinum–pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 376, 629–640 (2017).
Ramalingam, S. et al. Osimertinib versus standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. Ann. Oncol. 28 (Suppl. 5), v605–v649 (2017).
Heigener, D. F. & Reck, M. Crizotinib. Recent Results Cancer Res. 201, 197–205 (2014).
Tang, S. C. et al. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int. J. Cancer 134, 1484–1494 (2014).
Peters, S. et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 377, 829–838 (2017).
Hida, T. et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390, 29–39 (2017).
Carbone, D. P. et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426 (2017).
Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1–positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1709937 (2017).
D.F.H. and M.R. are advisory board members for, and have received honoraria for speaking and reimbursement for travel from Astra Zeneca, BMS, Boehringer Ingelheim, Lilly, MSD, Pfizer, and Roche. Both authors have also received honoraria for speaking from Chugai and Fresenius; D.F.H. is an advisory board member for both companies, and M.R. for Chugai.
About this article
Cite this article
Heigener, D., Reck, M. Giant steps and stumbling blocks. Nat Rev Clin Oncol 15, 71–72 (2018). https://doi.org/10.1038/nrclinonc.2017.178
Pathological Mechanistic Studies of Osimertinib Resistance in Non-Small-Cell Lung Cancer Cells Using an Integrative Metabolomics-Proteomics Analysis
Journal of Oncology (2020)
lncRNA JPX/miR-33a-5p/Twist1 axis regulates tumorigenesis and metastasis of lung cancer by activating Wnt/β-catenin signaling
Molecular Cancer (2020)
Circular RNA circ-SLC7A6 acts as a tumor suppressor in non-small cell lung cancer through abundantly sponging miR-21
Cell Cycle (2020)
<p>5-HT<sub>7</sub> Receptor Contributes to Proliferation, Migration and Invasion in NSCLC Cells</p>
OncoTargets and Therapy (2020)
TNBG‐5602, a novel derivative of quinoxaline, inhibits liver cancer growth via upregulating peroxisome proliferator‐activated receptor γin vitroandin vivo
Journal of Pharmacy and Pharmacology (2019)